| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 26 | 2025 | 3157 | 1.500 |
Why?
|
| Neoadjuvant Therapy | 10 | 2025 | 449 | 0.790 |
Why?
|
| Neoplasm Recurrence, Local | 10 | 2025 | 1471 | 0.580 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 6 | 2025 | 2642 | 0.410 |
Why?
|
| Lymph Node Excision | 2 | 2025 | 235 | 0.400 |
Why?
|
| Lymph Nodes | 3 | 2025 | 565 | 0.370 |
Why?
|
| Mastectomy | 4 | 2015 | 270 | 0.350 |
Why?
|
| Carcinoma, Ductal, Breast | 3 | 2022 | 166 | 0.350 |
Why?
|
| Receptor, ErbB-2 | 3 | 2023 | 280 | 0.350 |
Why?
|
| Hyperparathyroidism | 3 | 2002 | 65 | 0.340 |
Why?
|
| Mastectomy, Segmental | 3 | 2021 | 108 | 0.310 |
Why?
|
| Parathyroid Neoplasms | 2 | 2002 | 60 | 0.300 |
Why?
|
| Neoplasm Staging | 9 | 2025 | 2086 | 0.290 |
Why?
|
| Sentinel Lymph Node Biopsy | 3 | 2025 | 86 | 0.280 |
Why?
|
| Adenoma | 2 | 2002 | 260 | 0.260 |
Why?
|
| Aromatase Inhibitors | 1 | 2006 | 32 | 0.250 |
Why?
|
| Middle Aged | 27 | 2025 | 28369 | 0.240 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 2 | 2022 | 126 | 0.230 |
Why?
|
| Female | 36 | 2025 | 50030 | 0.230 |
Why?
|
| Sentinel Lymph Node | 1 | 2025 | 22 | 0.220 |
Why?
|
| Social Isolation | 1 | 2025 | 71 | 0.220 |
Why?
|
| Lymphadenopathy | 1 | 2024 | 20 | 0.210 |
Why?
|
| Prognosis | 9 | 2025 | 4028 | 0.210 |
Why?
|
| Cancer Survivors | 1 | 2025 | 88 | 0.200 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2024 | 104 | 0.200 |
Why?
|
| Adult | 23 | 2025 | 28722 | 0.200 |
Why?
|
| Chemotherapy, Adjuvant | 4 | 2025 | 518 | 0.200 |
Why?
|
| Aged | 19 | 2025 | 20968 | 0.190 |
Why?
|
| Carcinoma, Lobular | 2 | 2015 | 85 | 0.190 |
Why?
|
| Technetium Tc 99m Sestamibi | 1 | 2002 | 15 | 0.190 |
Why?
|
| Mammaplasty | 3 | 2013 | 124 | 0.190 |
Why?
|
| Healthcare Disparities | 2 | 2025 | 491 | 0.180 |
Why?
|
| Stress, Psychological | 1 | 2025 | 347 | 0.180 |
Why?
|
| Parathyroidectomy | 1 | 2002 | 79 | 0.180 |
Why?
|
| Reoperation | 5 | 2013 | 707 | 0.180 |
Why?
|
| Adenocarcinoma | 5 | 2003 | 1215 | 0.170 |
Why?
|
| Follow-Up Studies | 7 | 2025 | 3927 | 0.170 |
Why?
|
| Parathyroid Hormone | 1 | 2002 | 228 | 0.170 |
Why?
|
| Radiopharmaceuticals | 1 | 2002 | 204 | 0.170 |
Why?
|
| Combined Modality Therapy | 10 | 2023 | 1773 | 0.170 |
Why?
|
| Humans | 40 | 2025 | 96108 | 0.160 |
Why?
|
| Intestinal Neoplasms | 1 | 2001 | 70 | 0.160 |
Why?
|
| Body Weight | 1 | 2021 | 460 | 0.150 |
Why?
|
| Postoperative Complications | 4 | 2013 | 2592 | 0.150 |
Why?
|
| Survival Rate | 5 | 2025 | 1985 | 0.150 |
Why?
|
| Axilla | 3 | 2025 | 110 | 0.140 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2020 | 188 | 0.140 |
Why?
|
| Age Factors | 1 | 2023 | 1963 | 0.140 |
Why?
|
| Gastrinoma | 1 | 1996 | 2 | 0.130 |
Why?
|
| Zollinger-Ellison Syndrome | 1 | 1996 | 10 | 0.130 |
Why?
|
| BRCA1 Protein | 1 | 2018 | 216 | 0.130 |
Why?
|
| Urinary Catheterization | 1 | 2016 | 40 | 0.120 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2024 | 3639 | 0.120 |
Why?
|
| Radiotherapy | 3 | 2013 | 328 | 0.110 |
Why?
|
| Ultrasonography | 1 | 2017 | 747 | 0.110 |
Why?
|
| Biopsy | 3 | 2018 | 1220 | 0.110 |
Why?
|
| Aged, 80 and over | 9 | 2021 | 7229 | 0.110 |
Why?
|
| Retrospective Studies | 9 | 2025 | 10287 | 0.110 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2020 | 1021 | 0.100 |
Why?
|
| Crohn Disease | 1 | 2001 | 809 | 0.100 |
Why?
|
| Phyllodes Tumor | 1 | 2013 | 8 | 0.100 |
Why?
|
| Early Detection of Cancer | 1 | 2018 | 484 | 0.100 |
Why?
|
| Mass Screening | 1 | 2018 | 710 | 0.100 |
Why?
|
| Esophageal Neoplasms | 4 | 2003 | 346 | 0.090 |
Why?
|
| Lymphokines | 3 | 2002 | 75 | 0.090 |
Why?
|
| Neoplasm, Residual | 2 | 2023 | 195 | 0.090 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2016 | 569 | 0.090 |
Why?
|
| Endothelial Growth Factors | 2 | 2002 | 55 | 0.080 |
Why?
|
| Pancreatic Neoplasms | 1 | 1996 | 725 | 0.080 |
Why?
|
| Proportional Hazards Models | 3 | 2021 | 901 | 0.080 |
Why?
|
| Breast | 2 | 2023 | 297 | 0.080 |
Why?
|
| Paclitaxel | 2 | 2019 | 497 | 0.080 |
Why?
|
| Clinical Competence | 1 | 2016 | 854 | 0.080 |
Why?
|
| Genetic Therapy | 2 | 2003 | 382 | 0.080 |
Why?
|
| Mammography | 3 | 2021 | 475 | 0.080 |
Why?
|
| Peptide Fragments | 2 | 2003 | 477 | 0.080 |
Why?
|
| Time Factors | 5 | 2013 | 5580 | 0.070 |
Why?
|
| Neoplasm Proteins | 2 | 2002 | 553 | 0.070 |
Why?
|
| Endothelium, Vascular | 4 | 2002 | 437 | 0.060 |
Why?
|
| Tumor Cells, Cultured | 6 | 2005 | 1049 | 0.060 |
Why?
|
| Cohort Studies | 2 | 2023 | 3110 | 0.060 |
Why?
|
| Prospective Studies | 3 | 2021 | 4671 | 0.060 |
Why?
|
| Neoplasm Invasiveness | 2 | 2019 | 580 | 0.060 |
Why?
|
| Tamoxifen | 1 | 2006 | 171 | 0.060 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2002 | 1346 | 0.060 |
Why?
|
| Glycine | 1 | 2005 | 96 | 0.060 |
Why?
|
| Cyclophosphamide | 1 | 2005 | 313 | 0.050 |
Why?
|
| Adjuvants, Immunologic | 1 | 2005 | 174 | 0.050 |
Why?
|
| Tumor Necrosis Factor-alpha | 3 | 2003 | 713 | 0.050 |
Why?
|
| Chicago | 2 | 2025 | 1506 | 0.050 |
Why?
|
| Radiation, Ionizing | 2 | 2000 | 124 | 0.050 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2005 | 276 | 0.050 |
Why?
|
| Radiotherapy, Adjuvant | 2 | 2015 | 315 | 0.050 |
Why?
|
| Adaptive Clinical Trials as Topic | 1 | 2022 | 7 | 0.050 |
Why?
|
| Mucin-1 | 1 | 2003 | 46 | 0.050 |
Why?
|
| Mice, Nude | 5 | 2003 | 830 | 0.050 |
Why?
|
| Socioeconomic Factors | 1 | 2025 | 640 | 0.050 |
Why?
|
| Intraoperative Period | 1 | 2002 | 98 | 0.050 |
Why?
|
| Adolescent | 4 | 2015 | 9896 | 0.050 |
Why?
|
| Collagen | 2 | 2000 | 306 | 0.050 |
Why?
|
| Antineoplastic Agents | 2 | 2005 | 2418 | 0.040 |
Why?
|
| Longitudinal Studies | 1 | 2025 | 1176 | 0.040 |
Why?
|
| Body Weights and Measures | 1 | 2021 | 26 | 0.040 |
Why?
|
| Coumarins | 1 | 2000 | 14 | 0.040 |
Why?
|
| Immediate-Early Proteins | 1 | 2002 | 164 | 0.040 |
Why?
|
| Young Adult | 3 | 2022 | 7026 | 0.040 |
Why?
|
| Neoplasm Transplantation | 4 | 2005 | 411 | 0.040 |
Why?
|
| Monitoring, Physiologic | 1 | 2002 | 273 | 0.040 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2005 | 1105 | 0.040 |
Why?
|
| Clinical Trials as Topic | 1 | 2025 | 1179 | 0.040 |
Why?
|
| Male | 6 | 2016 | 45865 | 0.040 |
Why?
|
| Neoplasm Grading | 1 | 2021 | 404 | 0.040 |
Why?
|
| Radiation-Sensitizing Agents | 1 | 1999 | 100 | 0.040 |
Why?
|
| Receptors, Steroid | 1 | 2019 | 43 | 0.040 |
Why?
|
| Heterocyclic Compounds, 3-Ring | 1 | 2019 | 44 | 0.040 |
Why?
|
| Trastuzumab | 1 | 2019 | 88 | 0.040 |
Why?
|
| Doxorubicin | 1 | 2019 | 304 | 0.030 |
Why?
|
| Neoplasms, Experimental | 1 | 1999 | 270 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2021 | 1546 | 0.030 |
Why?
|
| Body Mass Index | 1 | 2021 | 815 | 0.030 |
Why?
|
| Neovascularization, Pathologic | 1 | 1999 | 354 | 0.030 |
Why?
|
| Stress, Physiological | 1 | 1999 | 252 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2019 | 367 | 0.030 |
Why?
|
| Mice | 8 | 2005 | 12537 | 0.030 |
Why?
|
| Comorbidity | 1 | 2021 | 1011 | 0.030 |
Why?
|
| Anorexia | 1 | 1997 | 28 | 0.030 |
Why?
|
| ROC Curve | 1 | 2019 | 797 | 0.030 |
Why?
|
| Transplantation, Heterologous | 3 | 2003 | 376 | 0.030 |
Why?
|
| Thyroidectomy | 1 | 1997 | 173 | 0.030 |
Why?
|
| Antibodies, Monoclonal | 2 | 2002 | 1429 | 0.030 |
Why?
|
| Urinary Catheters | 1 | 2016 | 6 | 0.030 |
Why?
|
| Decision Trees | 1 | 1996 | 63 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2021 | 1957 | 0.030 |
Why?
|
| DNA-Binding Proteins | 1 | 2002 | 1267 | 0.030 |
Why?
|
| Lymphatic Metastasis | 1 | 2017 | 514 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2021 | 1877 | 0.030 |
Why?
|
| Registries | 1 | 2021 | 986 | 0.030 |
Why?
|
| Interleukin-6 | 1 | 1997 | 281 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2017 | 819 | 0.030 |
Why?
|
| Neoplasms | 2 | 2000 | 3248 | 0.030 |
Why?
|
| Intraoperative Complications | 1 | 1996 | 197 | 0.030 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2019 | 611 | 0.030 |
Why?
|
| Protein Biosynthesis | 1 | 1997 | 399 | 0.030 |
Why?
|
| Adipose Tissue | 1 | 1997 | 271 | 0.030 |
Why?
|
| Transcription Factors | 1 | 2002 | 1730 | 0.030 |
Why?
|
| Preoperative Care | 1 | 1996 | 418 | 0.030 |
Why?
|
| Surgical Procedures, Operative | 1 | 1996 | 219 | 0.030 |
Why?
|
| Education, Medical | 1 | 2016 | 252 | 0.020 |
Why?
|
| Cytokines | 1 | 1997 | 871 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 4 | 2000 | 3489 | 0.020 |
Why?
|
| Transcription, Genetic | 1 | 1997 | 1192 | 0.020 |
Why?
|
| Animals | 8 | 2005 | 28891 | 0.020 |
Why?
|
| Adenoviridae | 2 | 2003 | 342 | 0.020 |
Why?
|
| Genetic Vectors | 2 | 2003 | 446 | 0.020 |
Why?
|
| Umbilical Veins | 2 | 2000 | 46 | 0.020 |
Why?
|
| Cells, Cultured | 3 | 2000 | 2939 | 0.020 |
Why?
|
| Vascular Endothelial Growth Factors | 2 | 2002 | 55 | 0.020 |
Why?
|
| Carcinoma, Lewis Lung | 2 | 2000 | 24 | 0.020 |
Why?
|
| Phosphatidylcholines | 1 | 1990 | 53 | 0.020 |
Why?
|
| Inflammation | 1 | 1997 | 1063 | 0.020 |
Why?
|
| False Negative Reactions | 1 | 2010 | 63 | 0.020 |
Why?
|
| Radiation Tolerance | 2 | 2002 | 176 | 0.020 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 1990 | 311 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2018 | 2474 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 2 | 2003 | 996 | 0.020 |
Why?
|
| Gadolinium DTPA | 1 | 2010 | 255 | 0.020 |
Why?
|
| Vascular Endothelial Growth Factor A | 2 | 2002 | 403 | 0.020 |
Why?
|
| Recombinant Proteins | 2 | 2000 | 1034 | 0.020 |
Why?
|
| Mutation | 1 | 2018 | 4374 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2000 | 1973 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 2010 | 1619 | 0.010 |
Why?
|
| Escherichia coli | 2 | 2000 | 627 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2010 | 2039 | 0.010 |
Why?
|
| Radiodermatitis | 1 | 2005 | 10 | 0.010 |
Why?
|
| Injections, Intraperitoneal | 1 | 2005 | 103 | 0.010 |
Why?
|
| Contrast Media | 1 | 2010 | 1096 | 0.010 |
Why?
|
| Apoptosis | 2 | 2002 | 1756 | 0.010 |
Why?
|
| Mice, Inbred C3H | 1 | 2005 | 372 | 0.010 |
Why?
|
| Drug Synergism | 1 | 2005 | 317 | 0.010 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2005 | 528 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2005 | 1010 | 0.010 |
Why?
|
| Wound Healing | 1 | 2005 | 378 | 0.010 |
Why?
|
| Risk Factors | 1 | 2013 | 5961 | 0.010 |
Why?
|
| Random Allocation | 1 | 2003 | 325 | 0.010 |
Why?
|
| Luminescent Proteins | 1 | 2003 | 145 | 0.010 |
Why?
|
| Early Growth Response Protein 1 | 1 | 2002 | 58 | 0.010 |
Why?
|
| RNA, Messenger | 2 | 1999 | 2090 | 0.010 |
Why?
|
| Green Fluorescent Proteins | 1 | 2003 | 314 | 0.010 |
Why?
|
| Cell Line, Transformed | 1 | 2002 | 156 | 0.010 |
Why?
|
| Models, Animal | 1 | 2003 | 286 | 0.010 |
Why?
|
| Virus Replication | 1 | 2003 | 326 | 0.010 |
Why?
|
| Isocoumarins | 1 | 2000 | 7 | 0.010 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2002 | 224 | 0.010 |
Why?
|
| Collagen Type XVIII | 1 | 2000 | 4 | 0.010 |
Why?
|
| Endostatins | 1 | 2000 | 6 | 0.010 |
Why?
|
| Platelet Endothelial Cell Adhesion Molecule-1 | 1 | 2000 | 48 | 0.010 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2000 | 192 | 0.010 |
Why?
|
| Pichia | 1 | 2000 | 31 | 0.010 |
Why?
|
| Laminin | 1 | 2000 | 92 | 0.010 |
Why?
|
| Drug Combinations | 1 | 2000 | 214 | 0.010 |
Why?
|
| Proteoglycans | 1 | 2000 | 126 | 0.010 |
Why?
|
| Microcirculation | 1 | 2000 | 104 | 0.010 |
Why?
|
| Cell Separation | 1 | 2000 | 205 | 0.010 |
Why?
|
| Tumor Stem Cell Assay | 1 | 1999 | 41 | 0.010 |
Why?
|
| Cloning, Molecular | 1 | 2000 | 648 | 0.010 |
Why?
|
| Cell Survival | 1 | 2002 | 1030 | 0.010 |
Why?
|
| RNA, Neoplasm | 1 | 1999 | 89 | 0.010 |
Why?
|
| Culture Media, Conditioned | 1 | 1999 | 103 | 0.010 |
Why?
|
| Flow Cytometry | 1 | 2000 | 728 | 0.010 |
Why?
|
| Disease Progression | 1 | 2002 | 1562 | 0.010 |
Why?
|
| Ciliary Neurotrophic Factor | 1 | 1997 | 1 | 0.010 |
Why?
|
| Leukemia Inhibitory Factor | 1 | 1997 | 4 | 0.010 |
Why?
|
| Growth Inhibitors | 1 | 1997 | 41 | 0.010 |
Why?
|
| Cell Movement | 1 | 2000 | 816 | 0.010 |
Why?
|
| Glioblastoma | 1 | 1999 | 285 | 0.010 |
Why?
|
| Leptin | 1 | 1997 | 102 | 0.010 |
Why?
|
| Interleukin-4 | 1 | 1997 | 136 | 0.010 |
Why?
|
| Interleukins | 1 | 1997 | 134 | 0.010 |
Why?
|
| Interleukin-2 | 1 | 1997 | 248 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2000 | 1828 | 0.010 |
Why?
|
| Interleukin-10 | 1 | 1997 | 166 | 0.010 |
Why?
|
| Lipopolysaccharides | 1 | 1997 | 305 | 0.010 |
Why?
|
| Melanoma | 1 | 1999 | 497 | 0.010 |
Why?
|
| Recurrence | 1 | 1997 | 1219 | 0.010 |
Why?
|
| Kinetics | 1 | 1997 | 1562 | 0.010 |
Why?
|
| Nerve Tissue Proteins | 1 | 1997 | 515 | 0.010 |
Why?
|
| Proteins | 1 | 1997 | 816 | 0.010 |
Why?
|
| Chromatography, Thin Layer | 1 | 1990 | 33 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2002 | 3581 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2002 | 9175 | 0.000 |
Why?
|
| Lung Neoplasms | 1 | 1999 | 2463 | 0.000 |
Why?
|
| Diabetes Mellitus | 1 | 1990 | 771 | 0.000 |
Why?
|